NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Manchester, United Kingdom
- The Christie NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Voluntary informed consent.
- Aged at least 18 years.
- Diagnosis of locally advanced or metastatic RCC, Melanoma or NSCLC
- In the opinion of the investigator deemed suitable to receive first-line combination immunotherapy (RCC and MM) or combination immunotherapy and chemotherapy (NSCLC).
- Willingness to comply with scheduled trial procedures.
- Capable of performing own dry blood sampling procedure, or a carer who is willing and able to perform them.
Exclusion Criteria:
- Previous immunotherapy (including any CPI either as single agent on in combination, or high dose interleukin-2).
- Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements.
- Patients receiving long term oral anticoagulation deemed by the clinician to be at risk from daily finger pricking.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient adherence to protocol defined DBS time points.
Time Frame: 12 months
|
the number of DBS samples successfully collected against the number of total expected samples
|
12 months
|
|
Number of in-home DBS samples passing quality assurance checks in patients receiving CPI therapy by multi-cytokine ELISA.
Time Frame: 12 months
|
the number of DBS samples passing quality assurance checks against the number of DBS samples successfully collected.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compare cytokine concentrations by DBS sampling and intravenous blood sampling by multi-cytokine ELISA.
Time Frame: 12 months
|
The changes of cytokine concentrations will be estimated by the log-ratio of cytokine concentrations measured at two time points.
The trend of cytokine concentration during treatment will be estimated by fitting a linear regression model based on all cytokine concentrations collected during treatment.
|
12 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retrospective mapping of immune-related adverse events with cytokine concentrations over time by in-home DBS sampling.
Time Frame: 12 months
|
The association between these statistics and the development of immune-related adverse events will be estimated using a logistic regression analysis.
|
12 months
|
|
Patient reported outcomes from semi-structured interviews.
Time Frame: 12 months
|
The patient satisfaction level will be assessed by survey interviews.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Donna Graham, MD, The Christie NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Lung Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Skin Diseases
- Urologic Neoplasms
- Carcinoma
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Kidney Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin Neoplasms
- Skin and Connective Tissue Diseases
- Neoplasms
- Carcinoma, Renal Cell
- Carcinoma, Non-Small-Cell Lung
- Melanoma
Other Study ID Numbers
Other Study ID Numbers
- CFTSp181
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.